Evaxion A/S
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $EVAX in the last 7 days.
No SEC Form 4 filings for $EVAX in the last 30 days.
See all $EVAX insider activity →Evaxion A/S reported Q2 2026 revenue of $0 and a net loss of $3.7 million, improving from a $4.8 million loss in Q2 2025. Shares rose 5.4% to $3.32 as investors focused on pipeline progress and cash runway through H2 2027. The company's AI-Immunology™ platform is advancing vaccine candidates for cancer and infectious diseases.
Analysts maintained Buy ratings on Evaxion Biotech (EVAX) and Boston Scientific (BSX). Thomas Flaten set a $9.00 target for EVAX, while Matthew Taylor set a $60.00 target for BSX. Both stocks have consensus Buy ratings with significant upside potential according to TipRanks.
Evaxion A/S (EVAX) reported a Q2 2026 net loss of $3.7M, improving from the prior year. Cash reserves totaled $14M, extending runway into 2H 2027. The company advanced its cancer and infectious disease vaccine pipeline, with key data presentations and regulatory filings expected. EVAX stock rose 6.35% in pre-market trading.
Recent EVAX coverage spans earnings, technology and financial news.
Earnings beat expectations on loss reduction and cash runway, prompting modest price uptick.
Analyst upgrades may support short-term price appreciation.
Earnings miss may pressure the stock, but pipeline progress could support upside.
Earnings miss with modest loss but continued R&D progress; cash runway to 2027.
Earnings beat expectations on loss reduction; pipeline updates may boost investor confidence.
AlphAI scores every news story that mentions EVAX with an AI model for sentiment and relevance, and aggregates insider trades from Evaxion A/S's SEC EDGAR Form 4 filings. Figures refresh continuously.
Evaxion A/S reported Q2 2026 revenue of $0 and a net loss of $3.7 million, improving from a $4.8 million loss in Q2 2025. Shares rose 5.4% to $3.32 as investors focused on pipeline progress and cash runway through H2 2027. The company's AI-Immunology™ platform is advancing vaccine candidates for cancer and infectious diseases.
2 min readAnalysts maintained Buy ratings on Evaxion Biotech (EVAX) and Boston Scientific (BSX). Thomas Flaten set a $9.00 target for EVAX, while Matthew Taylor set a $60.00 target for BSX. Both stocks have consensus Buy ratings with significant upside potential according to TipRanks.
1 min readEvaxion A/S (EVAX) reported a Q2 2026 net loss of $3.7M, improving from the prior year. Cash reserves totaled $14M, extending runway into 2H 2027. The company advanced its cancer and infectious disease vaccine pipeline, with key data presentations and regulatory filings expected. EVAX stock rose 6.35% in pre-market trading.
2 min readEvaxion A/S (EVAX) reported Q2 2026 financial results, including a net loss of $3.7M. The company highlighted progress in its R&D pipeline, including upcoming data presentations for cancer vaccine candidates EVX-01, EVX-04, and EVX-05, as well as CMV vaccine EVX-V1. Evaxion also won the 2026 Prix Galien UK Award for Best digital health solution. The company expects its cash runway to extend into the second half of 2027.
3 min readEvaxion A/S (EVAX) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Evaxion announces business update and second quarter 2026 financial results COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides
2 min readEvaxion A/S (NASDAQ: EVAX) will release a business update and its Q2 2026 financial results on Aug. 20, 2026, before Nasdaq CM opens. Management will host a conference call and webcast at 14:30 CET/08:30 EST to present the update and results and take questions.
2 min readEvaxion A/S (NASDAQ: EVAX) will present three-year phase 2 efficacy data for personalized cancer vaccine EVX-01 at ESMO Congress 2026. The data come from an extension in advanced melanoma, including a third-year EVX-01 stand-alone arm. Prior two-year results reported ORR 75% (12/16) and 92% durable clinical benefit at two years, with no relapses.
2 min readEvaxion A/S (NASDAQ: EVAX) reported new preclinical poster data for its cytomegalovirus vaccine program EVX-V1 at IHW 2026 in Montreal. The company said AI-discovered T-cell epitopes improved control of acute infection, latency and reactivation in CMV-infected mice, complementing prior B-cell antigen results. EVX-V1 combines novel antigens with an AI-optimized gB antigen.
2 min readEvaxion A/S (NASDAQ: EVAX) will present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal on July 12, 2026. EVX-V1 combines AI-discovered antigens with AI-optimized gB. The data will support final antigen selection as the program advances.
3 min readEvaxion A/S (NASDAQ: EVAX) reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia. The company said EVX-04 is fully expressed and secreted in human cells and that its ERV tumor antigens trigger specific immune responses and targeted cell-killing in mice and human in vitro models across different immune profiles. Data will be presented in a June 13, 2026 EHA poster in Stockholm.
4 min read
